

41 State Street • Suite 900
 Albany, NY 12207
 518.462.2293
 www.nyhpa.org

FOR IMMEDIATE RELEASE:
 December 13, 2023

CONTACT:
 Leslie S. Moran
 518.462.2293
 (cell) 518.588.6655

HPA ON LATEST ICER REPORT ON “UNSUPPORTED” DRUG PRICE HIKES

The latest report from the Institute for Clinical and Economic Review (ICER) looking at pricing of top selling prescription drugs in the United States found that while price increases for many of these in 2022 had “substantial” impact on U.S. spending, they lacked adequate new evidence to support the higher cost of the drugs. According to ICER’s evaluation, price increases for eight of the top 10 prescription drugs were unsupported by any new clinical value, yet they accounted for \$1.27 billion in additional costs. The drugs identified were:

Drug (% price increase 2021-2022)	Condition
• Humira (7.11%)	Arthritis
• Darzalex (6.80%)	Cancer
• Ibrance (6.92%)	Metastatic Breast Cancer
• Prolia (7.64%)	Osteoporosis
• Xifaxan (6.48%)	IBS and Crohn’s Disease
• Xgeva (7.53%)	Cancer
• Perjeta (6.08%)	Breast Cancer
• Adcetris (8.69%)	Cancer

Source: ICER

The attached [issue brief](#) highlights ICER’s analysis. Since its inaugural report in 2019, ICER’s five reports have documented more than \$9.7 billion in added spending for drugs where the identified price increases were not supported by any added clinical benefit.

In light of ICER’s most recent report, the New York Health Plan Association (HPA) urged Governor Hochul to sign legislation – S.599-A/A.1707-A – that would require drug manufacturers to provide at least 60 days’ notice of their intention to raise the cost of a drug by more than 16%.

“The legislation is an important step to protect New Yorkers from out-of-control drug costs,” said Eric Linzer, HPA President & CEO. “Requiring advance notice of substantial price increases would provide an early warning to protect employers and consumers from rising prescription costs and hold drug companies accountable for the exorbitant prices they charge.”